国家保健服务计划分三年逐步推出肥胖性药物Mounjaro,针对有多种健康状况的250 000名病人。 NHS plans a 3-year phased rollout of obesity drug Mounjaro, targeting 250,000 patients with multiple health conditions.

美国国家卫生服务局计划在三年内逐步推出肥胖药物Mounjaro, 也称为提泽帕提德, 针对25万患者. The NHS plans a phased rollout of the obesity drug Mounjaro, also known as tirzepatide, over three years, targeting 250,000 patients. 最初,它将优先考虑那些与肥胖有关的多重健康状况的人。 Initially, it will prioritize those with multiple health conditions linked to obesity. 临床试验显示,在36周内,该药物的平均体重下降21%,这也有助于血糖管理。 Clinical trials showed an average weight loss of 21% over 36 weeks with the drug, which also assists with blood sugar management. 国家卫生和护理英才研究所将在发布最后指南之前审查这些建议。 The National Institute for Health and Care Excellence will review the proposals before final guidance is issued.